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Main text
Substantial advances have been made in the understanding
of the host response to sepsis, but progress in the develop-
ment of new therapeutic approaches has been disappoint-
ing [1]. A potential reason may be the heterogeneity of the
host response and the need to precisely match the right
therapy to the right patient. Unlike cancer where bio-
markers can be analyzed and therapeutic decisions can be
made over several days, decisions have to be made within
hours in septic patients. Therefore, there is interest in
using clinical markers to target therapies instead of using
complex biomarker panels. For example, if patients with a
particular chronic disease had a unique host response and
would benefit from a particular therapy, then the chronic
disease could be used to precisely target therapy. There are
several reasons to focus on chronic diseases as potential
targets. They are common in sepsis patients, they are
associated with higher risk of sepsis, and they are often
associated with poor outcomes. In particular, studies have
focused on diabetes because it is present in approximately
20 % of sepsis patients and is a known risk factor for
infection.
Along these lines, van Vught et al. [2] sought to under-
stand if diabetes was associated with a unique pattern of
host response in the Molecular Diagnosis and Risk Strati-
fication of Sepsis (MARS) project. They evaluated the im-
mune response in 1104 patients (241 with preexisting
diabetes and 863 without) at ICU admission. They used a
comprehensive panel of biomarkers to interrogate the
host response, a targeted approach (i.e., analyzing 15
plasma biomarkers implicated in the pathogenesis of sep-
sis) and an unbiased approach by analyzing whole genome
expression profiles in leukocytes. They then examined
whether preexisting treatment with insulin or metformin
had immunomodulatory effects. In their cohort, patients
with preexisting diabetes were older and had a higher bur-
den of comorbid conditions, in particular cardiovascular
disease, hypertension, and renal insufficiency. Disease se-
verity on ICU admission was similar in both patient
groups as reflected by Acute Physiology Scores. Patients
with known diabetes were more likely to be admitted with
urosepsis (17.4 % in diabetics versus 9.8 % in non-
diabetics), which was consistent with a trend towards
more Gram-negative infections in diabetics (58.5 versus
51.4 % in non-diabetics). ICU and hospital length of stay,
ICU-acquired complications, as well as 90-day mortality
were not different between patients with or without preex-
isting diabetes. Compared to healthy controls, patients ad-
mitted with sepsis showed a profound activation of the
cytokine (interleukin (IL)-6, IL-8, and IL-10), vascular
endothelium (soluble E-selectin, soluble ICAM-1, fractalk-
ine, and angiopoietin-2), and coagulation systems (ele-
vated D-Dimer levels, prolonged prothrombin time and
activated partial thromboplastin time) measured up to
4 days after ICU admission. However, none of these
markers differed between patients with or without preex-
isting diabetes. Similarly, neither treatment with insulin
nor metformin was associated with differences in clinical
outcomes, plasma biomarker levels, or blood leukocyte
genomic response after adjusting for baseline differences.
These findings combined with prior results where the
host response did not differ in pneumonia patients with
and without diabetes that presented to the emergency
department [3] suggest that large differences in host
response due to diabetes are unlikely to occur. A likely
explanation is that the exuberant host response of early
sepsis or septic shock overrides any differences due to
diabetes. However, it is possible that small differences
may still occur. It would be interesting to see whether
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the proinflammatoy response takes on a different trajec-
tory in diabetic patients after resolution of the hyper-
acute phase compared to non-diabetics. The lack of
influence of insulin and metformin on the acute host re-
sponse is difficult to interpret as there is no objective
measure of medication adherence prior to hospitalization.
It is possible that patient’s compliance with home medica-
tions decreases in the days leading up to hospitalization
for a critical illness like sepsis, which may have attenuated
any existing immunomodulatory effect. Finally, given pre-
clinical data that suggest insulin-mediated modulation of
local inflammation [4], trying to assess local compartmen-
tal inflammation (e.g. lungs or kidneys) may be worthwile
pursuing in addition to the overall systemic inflammatory
response.
A result that may surprise some is that diabetes was
not associated with higher mortality. Indeed, studies
examining the association between diabetes and out-
comes have shown conflicting results, ranging from
higher mortality, no effect, to being protective [3, 5–7].
How do we reconcile these differences? Diabetes could
affect outcomes by modifying the risk of developing an
infection, increasing the risk of organ dysfunction once
infection occurs, and increasing the subsequent mortal-
ity. Some studies examining the association between dia-
betes and outcomes have enrolled patients early during
the hospital course, while others have focused on pa-
tients with sepsis who are in the ICU. If diabetes merely
increases the risk of acquiring an infection and develop-
ing organ dysfunction, analyzing patients who are in the
ICU alone may underestimate the association between
diabetes and outcomes of sepsis. Another reason for the
conflicting results could be differences in statistical
models with variability in including chronic conditions
associated with diabetes and likely to worsen outcomes,
such as kidney disease and cardiovascular disease.
In summary, the host response to severe infection is
very complex and remains incompletely understood.
Chronic conditions, such as diabetes, are unlikely to ex-
plain the heterogeneity in the host response to sepsis.
Only continuing efforts such as this study by van Vught
et al. will allow us to decipher the complex host re-
sponse and develop precise approaches to target novel
therapies.
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